1 Petrou S, Gray A. Economic evaluation alongside randomised clinical trials: design,
conduct, analysis and reporting. BMJ 2011;342:d1548.
2 Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic
evaluation for health care decision making? Health Econ 2006;15:677-87.
3 Briggs A, Claxton C, Sculpher M. Decision modelling for health economic evaluation .
Oxford University Press, 2006.
4 Gray A, Clarke P, Wolstenholme J, Wordsworth S. Applied methods of cost-effectiveness
analysis in health care . Oxford University Press, 2010.
5 Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic
evaluations: recommendations for the design, analysis, and reporting of studies. Int J
Technol Assess 2005;21:165-71.
6 Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart G. Methods for the
economic evaluation of health care programmes . 3rd ed. Oxford University Press, 2005.
7 Bojke L, Hornby E, Sculpher M. A comparison of the cost-effectiveness of pharmacotherapy
or surgery (laparoscopic fundoplication) in the treatment of GORD. Pharmacoeconomics
2007;25:829-41.
8 Legood R, Gray A, Wolstenholme J, Moss S, LBC/HPV Cervical Screening Pilot Studies
Group. The lifetime effects, costs and cost-effectiveness of using HPV testing to manage
low-grade cytological abnormalities: results of the NHS pilot studies. BMJ 2006;332:79-83.
9 Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess
Health Care 1989;5:559-75.
10 Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation
of health technologies. Health Econ 2006;15:1295-310.
11 Cooper K, Brailsford SC, Davies R. Choice of modelling technique for evaluating health
care interventions. J Oper Res Soc 2007;58:168-76.
12 Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of
herd-immunity. Med Decis Making 2003;23:76-82.
13 Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care:
selecting the appropriate approach. J Health Serv Res Policy 2004;9:110-8.
14 Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al.
Principles of good practice for decision analytic modeling in health-care evaluation: report
of the ISPOR Task Force on Good Research Practices—modeling studies. Value Health
2003;6:9-17.
15 NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research
on effectiveness: CRD’s guidance for those carrying out or commissioning reviews . NHS
CRD, University of York, 2001.
16 Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of
guidelines for good practice in decision-analytic modelling in health technology assessment.
Health Technol Assess 2004;8:iii-xi,1.
17 Golder S, Glanville J, Ginnelly L. Populating decision-analytic models: the feasibility and
efficiency of database searching for individual parameters. Int J Technol Assess Health
Care 2005;21:305-11.
18 Coyle D, Lee LM. The problem of protocol driven costs in pharmacoeconomic analysis.
Pharmacoeconomics 1998;14:357-63.
19 Ades AE, Sutton A. Multiparameter evidence synthesis in epidemiology and medical
decision-making: current approaches. J R Stat Soc 2006;169:5-35.
20 Weinstein MC. Recent developments in decision-analytic modelling for economic
evaluation. Pharmacoeconomics 2006;24:1043-53.
21 Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies
and frequently asked questions. Health Econ 2004;13:405-15.
22 Clarke PM, Gray AM, Briggs A, Farmer A, Fenn P, Stevens R, et al. A model to estimate
the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom
Prospective Diabetes Study (UKPDS) outcomes model. Diabetologia 2004;47:1747-59.
23 Mount Hood. Computer modeling of diabetes and its complications: a report on the fourth
Mount Hood challenge meeting. Diabetes Care 2007;30:1638-46.
24 Bojke L, Claxton K, Sculpher M, Palmer S. Characterizing structural uncertainty in decision
analytic models: a review and application of methods. Value Health 2009;12:739-49.
25 Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials:
importance, indications, and interpretation. Lancet 2005;365:176-86.
26 Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R, et al. Cost-effectiveness
of simvastatin in people at different levels of vascular disease risk: a randomised trial in
20 536 individuals. Lancet 2005;365:1779-85.
27 Mihaylova B, Briggs A, Armitage J, Parish S, Gray, A, Collins R. Lifetime cost effectiveness
of simvastatin in a range of risk groups and age groups derived from a randomised trial
of 20 536 people. BMJ 2006;333:1145-8.
28 Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for
decision-analytic modelling in health technology assessment: a review and consolidation
of quality assessment. Pharmacoeconomics 2006;24:355-71.
29 Stout NK, Knudsen AB, Kong CK, McMahon PM, Gazelle GS. Calibration methods used
in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics
2009;27:533-45.
30 Ades AE, Cliffe S. Markov chain Monte Carlo estimation of a multi-parameter decision
model: consistency of evidence and the accurate assessment of uncertainty. Med Decis
Making 2002;22:359-71.
31 Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S. A pilot study on the use of decision
theory and value of information analysis as part of the NHS health technology assessment
programme. Health Technol Assess 2004;8:1-103,iii.
32 Philips Z, Claxton K, Palmer S. The half-life of truth: appropriate time horizons for research
decisions? Med Decis Making 2008;28:287-99.
33 Speight PM, Palmer S, Moles DR, Downer MC, Smith DH, Henriksson M, et al. The
cost-effectiveness of screening for oral cancer in primary care. Health Technol Assess
2006;10:1-144,iii-iv.
34 Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, et al. The
cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol
Assess 2006;10:iii-iv,ix-xii,1-93.